Showing 14,921 - 14,940 results of 122,478 for search '(( 2 d decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.83s Refine Results
  1. 14921
  2. 14922

    Decreases in Colonic and Systemic Inflammation in Chronic HIV Infection after IL-7 Administration by Irini Sereti (244566)

    Published 2014
    “…Plasma levels of sCD14 and D-dimer, indicative of systemic inflammation, decreased after r-hIL-7. …”
  3. 14923
  4. 14924
  5. 14925

    Electrospun Gold Nanoprism/Poly(vinyl alcohol) Nanofibers for Flexible and Free-Standing Surface-Enhanced Raman Scattering Substrates by Alei Dang (1707214)

    Published 2022
    “…In this work, we demonstrate water-stable nanofibers as active SERS substrates electrospun from anisotropic gold nanoprisms (AuNPs) mixed with poly­(vinyl alcohol) (PVA) at a concentration of 2.5–20 nM, followed by cross-linking by glutaraldehyde (GA) vapor at room temperature. …”
  6. 14926

    Overexpression of POLDIP3 inhibits PDCoV replication in IPEC-J2 cells. by Yang Wu (66682)

    Published 2023
    “…<p>(A) IPEC-J2 cells were transduced with a bicistronic lentivirus vector expressing ZsGreen alone (vector control) or POLDIP3 plus ZsGreen as described in Materials and Methods. …”
  7. 14927
  8. 14928
  9. 14929
  10. 14930
  11. 14931
  12. 14932
  13. 14933

    GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis by Guillaume Grenet (6748583)

    Published 2019
    “…<div><p>Background</p><p>The last international consensus on the management of type 2 diabetes (T2D) recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV) disease; metformin remains the first-line glucose lowering medication. …”
  14. 14934
  15. 14935
  16. 14936
  17. 14937
  18. 14938
  19. 14939
  20. 14940

    Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera by Angela Bozza (8908091)

    Published 2023
    “…After the discovery of a mutation in the Janus kinase 2 (<i>JAK</i>2<sup>V617F</sup>), JAK2 inhibitors have been tested as second-line therapies. …”